Novavax Q4 GAAP EPS $(1.44) May Not Be Comparable To $(0.45) Estimate, Sales $291.34M Miss $321.97M Estimate
Portfolio Pulse from Benzinga Newsdesk
Novavax reported Q4 GAAP EPS of $(1.44), missing the $(0.45) estimate by 220%, and sales of $291.34M, missing the $321.97M estimate by 9.51%. This represents a 36.84% decrease in losses and an 18.48% decrease in sales from the same period last year.
February 28, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novavax's Q4 earnings missed estimates with a GAAP EPS of $(1.44) and sales of $291.34M, indicating a significant underperformance compared to expectations.
The significant miss in both EPS and sales estimates for Novavax in Q4 suggests a negative short-term impact on the stock price. The company's performance fell short of analyst expectations by a considerable margin, which typically leads to negative investor sentiment and could result in a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100